Real-World Experience of Patient-Relevant Benefits and Treatment Satisfaction with Apremilast in Patients with Psoriasis: An Analysis of the APPRECIATE Study

Toni Maria Klein; Christine Blome; C Elise Kleyn; Curdin Conrad; Paul G Sator; Mona Ståhle; Kilian Eyerich; Marc Alexander Radtke; Christine Bundy; Myriam Cordey; Christopher E M Griffiths; Matthias Augustin

doi:10.1007/s13555-021-00628-3

Real-World Experience of Patient-Relevant Benefits and Treatment Satisfaction with Apremilast in Patients with Psoriasis: An Analysis of the APPRECIATE Study

Dermatol Ther (Heidelb). 2022 Jan;12(1):81-95. doi: 10.1007/s13555-021-00628-3. Epub 2021 Nov 23.

Authors

Affiliations

¹ Institute for Health Services Research in Dermatology and Nursing (IVDP), University Medical Center Hamburg-Eppendorf (UKE), Hamburg, Germany. T.Klein@uke.de.
² Institute for Health Services Research in Dermatology and Nursing (IVDP), University Medical Center Hamburg-Eppendorf (UKE), Hamburg, Germany.
³ The Dermatology Centre, NIHR Manchester Biomedical Research Centre, Salford Royal Hospital, The University of Manchester, Manchester, UK.
⁴ Department of Dermatology, Lausanne University Hospital CHUV and University of Lausanne, Lausanne, Switzerland.
⁵ Department of Dermatology, Clinic Hietzing, Vienna, Austria.
⁶ Unit of Dermatology, Department of Medicine, Karolinska Institutet, Stockholm, Sweden.
⁷ Department of Dermatology and Allergy, Technical University of Munich, Munich, Germany.
⁸ Dermatologikum Hamburg, Hamburg, Germany.
⁹ College of Biomedical and Health Sciences, Cardiff University, Cardiff, UK.
¹⁰ Amgen Europe GmbH, Rotkreuz, Switzerland.

Abstract

Introduction: In the real-world APPRECIATE study (NCT02740218), most patients with psoriasis demonstrated notable improvements on disease severity measures and reported clinically meaningful treatment benefits with apremilast.

Objective: We aim to further describe patient-relevant needs and benefits and patient satisfaction with apremilast, including subgroup analyses based on patient characteristics.

Methods: APPRECIATE, a multinational, retrospective, cross-sectional study, enrolled patients with chronic plaque psoriasis who started apremilast according to the European label. Patient Benefit Index (PBI; range 0 (no patient-relevant benefit) to 4 (maximum patient-relevant benefit), global PBI score ≥ 1 indicating minimum patient-relevant benefit and ≥ 3 indicating high benefit) and nine-item Treatment Satisfaction Questionnaire for Medication (TSQM-9; range 0-100) were assessed 6 (± 1) months after apremilast initiation and summarized descriptively. Relationships between global PBI and TSQM-9 assessments were analyzed by Pearson correlations.

Results: Of 480 enrolled patients, 347 (72.3%) had remained on apremilast at 6 (± 1) months; 90.9% (300/330) achieved global PBI score ≥ 1. Mean (standard deviation) global PBI score was 2.8 (1.2). Higher achievement of global PBI score ≥ 3 was observed in patients with no prior treatments (61.1% (22/36)) or prior phototherapy (64.6% (42/65)) versus prior conventional systemic (54.4% (100/184)) or biologic (38.6% (17/44)) treatment. Strong correlations were observed between the global PBI score and the TSQM-9 global satisfaction and effectiveness subscale scores.

Conclusion: Patients continuing apremilast for 6 (± 1) months in APPRECIATE reported patient-relevant treatment benefits. Findings suggest that receiving apremilast earlier versus later in treatment management is consistent with greater improvements in patient-relevant treatment outcomes.

Keywords: Apremilast; Patient Benefit Index; Patient-reported outcomes; Psoriasis; Real-world study; Treatment satisfaction.